https://www.biopharmawatch.com/news/HCA/solis-mammography-hca-healthcare-charleston-partnership BiopharmaWatch en 2026-09-29T15:36:00.000Z SOLIS MAMMOGRAPHY AND HCA HEALTHCARE CHARLESTON PARTNER TO EXPAND BREAST HEALTH SERVICES IN SOUTH CAROLINA https://www.biopharmawatch.com/news/GMAB/genmab-s-published-articles-association-20260929 BiopharmaWatch en 2026-09-29T13:32:30.000Z Genmab A/S has published its Articles of Association https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-liver-cancer-immunotherapy BiopharmaWatch en 2026-09-29T13:30:00.000Z Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy https://www.biopharmawatch.com/news/VALN/new-approach-to-travel-health-valn BiopharmaWatch en 2026-09-29T13:15:47.000Z A changing world, a new approach to travel health https://www.biopharmawatch.com/news/ARQT/simone-biles-arcutis-skin-to-believe-in-campaign BiopharmaWatch en 2026-09-29T13:15:31.000Z Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options https://www.biopharmawatch.com/news/ERNA/ernexa-selected-emerging-track-cell-gene-meeting BiopharmaWatch en 2026-09-29T13:15:00.000Z Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy https://www.biopharmawatch.com/news/TXG/10x-genomics-sentira-computational-platform-launch BiopharmaWatch en 2026-09-29T13:01:00.000Z 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions https://www.biopharmawatch.com/news/ALNY/amvuttra-play-by-play-initiative-attr-cm BiopharmaWatch en 2026-09-29T13:00:00.000Z AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM https://www.biopharmawatch.com/news/BDX/bdx-70-years-manufacturing-sandy-utah BiopharmaWatch en 2026-09-29T13:00:00.000Z BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy https://www.biopharmawatch.com/news/TXG/10x-genomics-begins-global-shipments-of-atera BiopharmaWatch en 2026-09-29T13:00:00.000Z 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands https://www.biopharmawatch.com/news/ABBV/abbvie-partners-valkai-advanced-ai-clinical-development BiopharmaWatch en 2026-09-29T13:00:00.000Z AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development https://www.biopharmawatch.com/news/NXL/nexalin-technology-global-commercialization-strategy BiopharmaWatch en 2026-09-29T13:00:00.000Z Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-29T13:00:00.000Z Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule https://www.biopharmawatch.com/news/NTHI/neonc-s-powerful-brain-cancer-pipeline-advances BiopharmaWatch en 2026-09-29T12:52:00.000Z NeOnc’s Powerful Brain Cancer Pipeline Advances https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-phase-2-3-miracle-trial-enrollment-complete BiopharmaWatch en 2026-09-29T12:45:00.000Z Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-cost-reduction-revenue-growth BiopharmaWatch en 2026-09-29T12:45:00.000Z Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives https://www.biopharmawatch.com/news/ICU/seastar-medical-cmo-presents-ppets-2026 BiopharmaWatch en 2026-09-29T12:36:00.000Z SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026 https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-fda-vote-onetest BiopharmaWatch en 2026-09-29T12:31:00.000Z 20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model https://www.biopharmawatch.com/news/QTI/qt-imaging-nasdaq-closing-bell-breast-cancer-awareness BiopharmaWatch en 2026-09-29T12:30:00.000Z QT Imaging to Ring the Nasdaq Closing Bell on October 2 in Recognition of Breast Cancer Awareness Month https://www.biopharmawatch.com/news/FBLG/fibrobiologics-european-patent-fibroblast-therapy BiopharmaWatch en 2026-09-29T12:30:00.000Z FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity https://www.biopharmawatch.com/news/CELU/celularity-naveen-jain-board-appointment BiopharmaWatch en 2026-09-29T12:30:00.000Z Celularity Announces Naveen Jain to Join Board of Directors https://www.biopharmawatch.com/news/LITS/lite-strategy-fiscal-year-2026-results BiopharmaWatch en 2026-09-29T12:30:00.000Z Lite Strategy Reports Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-corporate-update-financial-results-2026 BiopharmaWatch en 2026-09-29T12:30:00.000Z Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results https://www.biopharmawatch.com/news/TARS/tarsus-presents-11-abstracts-aaopt-2026 BiopharmaWatch en 2026-09-29T12:30:00.000Z Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting https://www.biopharmawatch.com/news/MLSS/milestone-scientific-scalable-growth-platform-compuflo BiopharmaWatch en 2026-09-29T12:30:00.000Z Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business https://www.biopharmawatch.com/news/IART/integra-lifesciences-aera-pediatric-registry-100th-patient BiopharmaWatch en 2026-09-29T12:30:00.000Z Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry https://www.biopharmawatch.com/news/VOR/telitacicept-minimal-symptom-expression-gmg BiopharmaWatch en 2026-09-29T12:05:27.000Z Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-exercise-warrants BiopharmaWatch en 2026-09-29T12:03:00.000Z Silexion Therapeutics Announces Exercise of Warrants https://www.biopharmawatch.com/news/PFE/isomab-appoints-bill-sessa-chair-scientific-advisory-board BiopharmaWatch en 2026-09-29T12:03:00.000Z Professor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board https://www.biopharmawatch.com/news/ACXP/acurx-pathfinder-trial-ibezapolstat-cdi BiopharmaWatch en 2026-09-29T12:01:00.000Z Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection https://www.biopharmawatch.com/news/ABBV/ginkgo-apheris-abbvie-argenx-lundbeck-takeda-consortium BiopharmaWatch en 2026-09-29T12:00:00.000Z Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium https://www.biopharmawatch.com/news/A/agilent-gen5-ai-cell-identification-module-launch BiopharmaWatch en 2026-09-29T12:00:00.000Z Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers https://www.biopharmawatch.com/news/LTRN/lantern-pharma-8-million-offering BiopharmaWatch en 2026-09-29T12:00:00.000Z Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-shareholders-voucher BiopharmaWatch en 2026-09-29T12:00:00.000Z Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher https://www.biopharmawatch.com/news/NVS/cas-gibt-zusammenarbeit-mit-novartis-bekannt-um-die-ki-fahige BiopharmaWatch en 2026-09-29T12:00:00.000Z CAS gibt Zusammenarbeit mit Novartis bekannt, um die KI-fähige Reaktionsinformatik voranzutreiben https://www.biopharmawatch.com/news/NVS/cas-novartis-ai-research-collaboration BiopharmaWatch en 2026-09-29T12:00:00.000Z CAS anuncia una colaboración con Novartis para impulsar la informática de reacciones preparada para la IA https://www.biopharmawatch.com/news/NVS/cas-novartis-ai-reaction-informatics BiopharmaWatch en 2026-09-29T12:00:00.000Z CAS announces collaboration with Novartis to advance AI-ready reaction informatics https://www.biopharmawatch.com/news/IMNN/imunon-debt-to-equity-conversion BiopharmaWatch en 2026-09-29T12:00:00.000Z IMUNON Converts $1.2 Million of Debt-to-Equity https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-fall-2026-conference BiopharmaWatch en 2026-09-29T12:00:00.000Z Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/BBNX/beta-bionics-third-quarter-2026-results-announcement BiopharmaWatch en 2026-09-29T12:00:00.000Z Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026 https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-phase-1-results-tx2100-hht BiopharmaWatch en 2026-09-29T12:00:00.000Z Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-spinoza-trial-obicetrapib-alzheimers BiopharmaWatch en 2026-09-29T12:00:00.000Z NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease https://www.biopharmawatch.com/news/APYX/apyx-medical-renuvion-clinical-study-results BiopharmaWatch en 2026-09-29T12:00:00.000Z Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality https://www.biopharmawatch.com/news/PHAT/phathom-phase-3-study-voquezna-non-erosive-gerd BiopharmaWatch en 2026-09-29T12:00:00.000Z Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD https://www.biopharmawatch.com/news/NSRX/nasus-pharma-phase-1-study-ns003-ondansetron BiopharmaWatch en 2026-09-29T12:00:00.000Z Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron https://www.biopharmawatch.com/news/DNTH/dianthus-claseprubart-2026-aanem-meeting BiopharmaWatch en 2026-09-29T12:00:00.000Z Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting https://www.biopharmawatch.com/news/KROS/keros-therapeutics-takeda-milestone-payment BiopharmaWatch en 2026-09-29T12:00:00.000Z Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda https://www.biopharmawatch.com/news/ARGX/argenx-new-data-aanem-mgfa-sessions BiopharmaWatch en 2026-09-29T12:00:00.000Z argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-lucas-donigian-business-development BiopharmaWatch en 2026-09-29T12:00:00.000Z Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development https://www.biopharmawatch.com/news/CRBP/corbus-tempo-1-study-crb-701-oropharyngeal-cancer BiopharmaWatch en 2026-09-29T12:00:00.000Z Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer https://www.biopharmawatch.com/news/GLAS/glass-house-brands-cfo-retirement-announcement BiopharmaWatch en 2026-09-29T11:35:00.000Z Glass House Brands Announces Planned Retirement of Chief Financial Officer https://www.biopharmawatch.com/news/ARWR/arrowhead-webinar-aro-mapt-alzheimers-study BiopharmaWatch en 2026-09-29T11:30:00.000Z Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-preclinical-data-intranasal-dosing BiopharmaWatch en 2026-09-29T11:30:00.000Z Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-phase-2-clover-wam-data BiopharmaWatch en 2026-09-29T11:30:00.000Z Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia https://www.biopharmawatch.com/news/MDCX/medicus-pharma-teverelix-fda-submission BiopharmaWatch en 2026-09-29T11:30:00.000Z Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer https://www.biopharmawatch.com/news/OPTH/optimi-health-appoints-melanie-pump-board-directors BiopharmaWatch en 2026-09-29T11:30:00.000Z Optimi Health Appoints Melanie Pump to Board of Directors https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-descartes-08-retreatment-data BiopharmaWatch en 2026-09-29T11:30:00.000Z Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-schedules-type-c-meeting-fda-align-endpoints-phase BiopharmaWatch en 2026-09-29T11:30:00.000Z Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB https://www.biopharmawatch.com/news/QURE/uniqure-phase-i-ii-ifezuntirgene-inilparvovec-huntingtons-disease BiopharmaWatch en 2026-09-29T11:12:00.000Z uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression https://www.biopharmawatch.com/news/IMCC/im-cannabis-sale-imc-holdings-european-operations BiopharmaWatch en 2026-09-29T11:07:00.000Z IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-resubmission-ndas-oxylanthanum-carbonate BiopharmaWatch en 2026-09-29T11:05:00.000Z Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate https://www.biopharmawatch.com/news/IMMX/immix-biopharma-125-million-offering BiopharmaWatch en 2026-09-29T11:05:00.000Z Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock https://www.biopharmawatch.com/news/OCGN/ocugen-participate-october-investor-conferences BiopharmaWatch en 2026-09-29T11:02:00.000Z Ocugen to Participate in Upcoming October Investor and Industry Conferences https://www.biopharmawatch.com/news/BYSI/beyondspring-fda-fast-track-plinabulin-nsclc-trial BiopharmaWatch en 2026-09-29T11:01:00.000Z BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis https://www.biopharmawatch.com/news/IVVD/invivyd-liberty-phase-3-study-results-vyd2311 BiopharmaWatch en 2026-09-29T11:01:00.000Z Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 https://www.biopharmawatch.com/news/ALDX/aldeyra-fdr-request-reproxalap-dry-eye-disease BiopharmaWatch en 2026-09-29T11:00:00.000Z Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease https://www.biopharmawatch.com/news/ZLAB/zai-lab-global-data-zocilurtatug-es-sclc BiopharmaWatch en 2026-09-29T11:00:00.000Z Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-raises-revenue-guidance-2026 BiopharmaWatch en 2026-09-29T11:00:00.000Z Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-rich-daly-appointment BiopharmaWatch en 2026-09-29T11:00:00.000Z Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-pfizer-collaboration-milestone BiopharmaWatch en 2026-09-29T11:00:00.000Z Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer https://www.biopharmawatch.com/news/NRXS/neuraxis-appoints-craig-blanchard-cfo BiopharmaWatch en 2026-09-29T11:00:00.000Z NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer https://www.biopharmawatch.com/news/ACON/aclarion-nyu-langone-health-clarity-trial-network BiopharmaWatch en 2026-09-29T11:00:00.000Z Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nexicart-2-interim-update BiopharmaWatch en 2026-09-29T11:00:00.000Z Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ophthalmic-conferences-2026 BiopharmaWatch en 2026-09-29T11:00:00.000Z OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences https://www.biopharmawatch.com/news/TFX/teleflex-reduces-clabsi-risk-arrowgard-technology BiopharmaWatch en 2026-09-29T10:30:00.000Z Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology https://www.biopharmawatch.com/news/CAI/caris-life-sciences-enhanced-caris-assure-launch BiopharmaWatch en 2026-09-29T10:30:00.000Z Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure https://www.biopharmawatch.com/news/KURA/caspian-therapeutics-ko-7246-easd-diabetes BiopharmaWatch en 2026-09-29T09:15:00.000Z Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes https://www.biopharmawatch.com/news/EVO/evotec-chief-scientific-officer-transition BiopharmaWatch en 2026-09-29T06:04:00.000Z Evotec Announces Chief Scientific Officer Transition https://www.biopharmawatch.com/news/PHAR/pharming-ceo-transition-announcement BiopharmaWatch en 2026-09-29T05:00:00.000Z Pharming announces CEO transition https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-half-year-financial-report-2026 BiopharmaWatch en 2026-09-29T02:00:00.000Z Genflow Biosciences PLC Announces Half-year Financial Report https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-azure-1-study-brelovitug BiopharmaWatch en 2026-09-29T00:34:00.000Z Resumen: Mirum Pharmaceuticals anuncia que se ha cumplido el criterio de valoración principal en el estudio de fase III AZURE-1 sobre brelovitug para tratar la hepatitis crónica por el virus delta https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-phase-3-azure-1-study BiopharmaWatch en 2026-09-29T00:34:00.000Z Mirum Pharmaceuticals gibt bekannt, dass der primäre Endpunkt in der Phase-3-Studie AZURE-1 zu Brelovitug bei chronischer Hepatitis-Delta-Virus-Infektion erreicht wurde https://www.biopharmawatch.com/news/BLTE/belite-bio-upcoming-medical-conferences BiopharmaWatch en 2026-09-29T00:00:00.000Z Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences https://www.biopharmawatch.com/news/IGC/how-sleep-supports-brain-health BiopharmaWatch en 2026-09-28T22:48:25.000Z How Sleep Supports Brain Health https://www.biopharmawatch.com/news/VIVI/tempramed-announces-upsized-offering BiopharmaWatch en 2026-09-28T21:49:00.000Z TempraMed Announces Upsize to Offering https://www.biopharmawatch.com/news/SMMT/astrazeneca-investment-summit-therapeutics BiopharmaWatch en 2026-09-28T21:30:00.000Z AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics https://www.biopharmawatch.com/news/AZN/eccogene-50-million-milestone-astrazeneca-phase-3 BiopharmaWatch en 2026-09-28T21:21:00.000Z Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004) https://www.biopharmawatch.com/news/PREV/preveceutical-announces-private-placement BiopharmaWatch en 2026-09-28T21:00:00.000Z PreveCeutical Announces Non-Brokered Private Placement https://www.biopharmawatch.com/news/DTC/defence-therapeutics-corporate-update-strategic-priorities BiopharmaWatch en 2026-09-28T21:00:00.000Z Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-2027-first-quarter-results BiopharmaWatch en 2026-09-28T20:30:00.000Z AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 https://www.biopharmawatch.com/news/ALGN/align-technology-shift-happens-campaign BiopharmaWatch en 2026-09-28T20:30:00.000Z Align Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement https://www.biopharmawatch.com/news/ALDX/aldeyra-regulatory-update-webcast-september-2026 BiopharmaWatch en 2026-09-28T20:30:00.000Z Aldeyra Therapeutics to Host Regulatory Update Webcast https://www.biopharmawatch.com/news/NYXH/nyxoah-nomme-liam-kelly-ceo BiopharmaWatch en 2026-09-28T20:30:00.000Z Nyxoah Nomme Liam Kelly au Poste de Chief Executive Officer https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-liam-kelly-ceo BiopharmaWatch en 2026-09-28T20:30:00.000Z Nyxoah Appoints Liam Kelly as Chief Executive Officer https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-fiscal-2026-results BiopharmaWatch en 2026-09-28T20:30:00.000Z Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results https://www.biopharmawatch.com/news/POCI/precision-optics-fy-2026-financial-results BiopharmaWatch en 2026-09-28T20:30:00.000Z Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-upsized-offerings-575-million BiopharmaWatch en 2026-09-28T20:30:00.000Z Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes https://www.biopharmawatch.com/news/VSTM/verastem-oncology-ramp-201-study-results BiopharmaWatch en 2026-09-28T20:10:00.000Z Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer https://www.biopharmawatch.com/news/SIBN/si-bone-fda-clearance-ifuse-granite-onyx BiopharmaWatch en 2026-09-28T20:09:00.000Z SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-patent-trofinetide-2023 BiopharmaWatch en 2026-09-28T20:05:00.000Z Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-announces-new-employee-inducement-grants-20260928 BiopharmaWatch en 2026-09-28T20:01:00.000Z Definium Therapeutics Announces New Employee Inducement Grants https://www.biopharmawatch.com/news/TEVA/teva-fda-approval-degevma-biosimilar-xgeva BiopharmaWatch en 2026-09-28T20:00:00.000Z Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) https://www.biopharmawatch.com/news/MOH/molina-healthcare-grants-genesee-county-sdoh BiopharmaWatch en 2026-09-28T19:00:00.000Z Molina Healthcare of Michigan and The MolinaCares Accord Award $160,000 in Grants to Genesee County-Area Organizations Addressing Social Determinants of Health https://www.biopharmawatch.com/news/MPH/medicure-completes-enrollment-mend-pnpo-trial BiopharmaWatch en 2026-09-28T18:00:00.000Z Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial https://www.biopharmawatch.com/news/NRSN/neurosense-participate-roth-healthcare-conference BiopharmaWatch en 2026-09-28T16:43:00.000Z NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-brelovitug-phase-3-study-success BiopharmaWatch en 2026-09-28T16:28:00.000Z Riassunto: Mirum Pharmaceuticals annuncia che brelovitug ha raggiunto l'endpoint primario dello studio di Fase 3 AZURE-1 per il trattamento del virus dell'epatite cronica Delta https://www.biopharmawatch.com/news/MIRM/samenvatting-mirum-pharmaceuticals-maakte-bekend-dat-het-primaire-eindpunt-bereikt BiopharmaWatch en 2026-09-28T16:28:00.000Z Samenvatting: Mirum Pharmaceuticals maakte bekend dat het primaire eindpunt is bereikt in de Fase 3 AZURE-1 studie van brelovitug bij chronische hepatitis delta-virus https://www.biopharmawatch.com/news/ALC/systane-pro-preservative-free-launch-canada BiopharmaWatch en 2026-09-28T14:15:00.000Z Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-pipeline-advances BiopharmaWatch en 2026-09-28T13:51:00.000Z Powerful NeOnc Brain Cancer Pipeline Advances https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20260928 BiopharmaWatch en 2026-09-28T13:50:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/ONCY/oncolytics-reo-033-colorectal-cancer-study-update BiopharmaWatch en 2026-09-28T13:30:00.000Z Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study https://www.biopharmawatch.com/news/ESYN/enersyn-global-nigeria-energy-investment-lagos-cng-project BiopharmaWatch en 2026-09-28T13:10:00.000Z EnerSyn Global Inc. Announces Second Nigeria Energy Investment: Lagos CNG Mother Station Project https://www.biopharmawatch.com/news/HYPD/hyperion-defi-d3-frontier-vault-launch BiopharmaWatch en 2026-09-28T13:06:00.000Z Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem https://www.biopharmawatch.com/news/PZZA/shareholders-who-lost-money-shares-acquired-papa-john-s-international-20260928 BiopharmaWatch en 2026-09-28T13:04:00.000Z Shareholders who lost money in shares of acquired Papa John's International, Inc. (NASDAQ: PZZA) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/MMED/minimed-appoints-sheila-denton-general-counsel BiopharmaWatch en 2026-09-28T13:03:00.000Z MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary https://www.biopharmawatch.com/news/CV/capsovision-fda-clearance-ai-highlights-capsocam-plus BiopharmaWatch en 2026-09-28T13:00:00.000Z CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus® https://www.biopharmawatch.com/news/LINC/lincoln-educational-services-class-action-lawsuit BiopharmaWatch en 2026-09-28T12:57:00.000Z Shareholders who lost money in shares of acquired Lincoln Educational Services Corporation (NASDAQ: LINC) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-ueg-week-2026 BiopharmaWatch en 2026-09-28T12:50:00.000Z Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-acquisition-webster-equity-partners BiopharmaWatch en 2026-09-28T12:45:00.000Z Lifecore Biomedical to be Acquired by Webster Equity Partners https://www.biopharmawatch.com/news/GRI/gri-bio-ipf-summit-2026-insights BiopharmaWatch en 2026-09-28T12:40:00.000Z GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-positive-preclinical-findings-sil204 BiopharmaWatch en 2026-09-28T12:30:00.000Z Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-cheast-2026 BiopharmaWatch en 2026-09-28T12:30:00.000Z Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 https://www.biopharmawatch.com/news/CARL/carlsmed-appoints-richard-heppenstall-cfo BiopharmaWatch en 2026-09-28T12:30:00.000Z Carlsmed Appoints Richard Heppenstall as Chief Financial Officer https://www.biopharmawatch.com/news/IGC/igc-pharma-completes-enrollment-phase-2-calma-trial BiopharmaWatch en 2026-09-28T12:23:06.000Z IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026 https://www.biopharmawatch.com/news/DARE/dare-bioscience-new-patent-dare-hpv-program BiopharmaWatch en 2026-09-28T12:20:00.000Z Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection https://www.biopharmawatch.com/news/HYPR/hyperfine-expands-global-access-portable-brain-mri BiopharmaWatch en 2026-09-28T12:15:00.000Z Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets https://www.biopharmawatch.com/news/PBM/psyence-biomed-exclusive-ibogaine-license BiopharmaWatch en 2026-09-28T12:11:20.000Z Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu-3-positive-data-diabetic-foot-ulcers BiopharmaWatch en 2026-09-28T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/NTHI/neonc-technologies-fda-end-of-phase-1-meeting-ne0212 BiopharmaWatch en 2026-09-28T12:00:42.000Z NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 https://www.biopharmawatch.com/news/NKTR/nektar-rezpegaldesleukin-eadv-2026-presentations BiopharmaWatch en 2026-09-28T12:00:00.000Z Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 https://www.biopharmawatch.com/news/LNTH/lantheus-sparrow-phase-2-3-trial-prostate-cancer BiopharmaWatch en 2026-09-28T12:00:00.000Z Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-phase-3-azure-1-study-brelovitug BiopharmaWatch en 2026-09-28T12:00:00.000Z Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-october-2026 BiopharmaWatch en 2026-09-28T12:00:00.000Z Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026 https://www.biopharmawatch.com/news/NCEL/newcelx-attends-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-09-28T12:00:00.000Z NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes https://www.biopharmawatch.com/news/ALXO/alx-oncology-evorpacept-gastric-cancer-data BiopharmaWatch en 2026-09-28T12:00:00.000Z ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer https://www.biopharmawatch.com/news/FDMT/4dmt-phase-3-trial-4d-150-dme BiopharmaWatch en 2026-09-28T12:00:00.000Z 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME https://www.biopharmawatch.com/news/KROS/keros-therapeutics-phase-2-dosing-rinvatercept-dmd BiopharmaWatch en 2026-09-28T12:00:00.000Z Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD https://www.biopharmawatch.com/news/HUMA/humacyte-expands-board-expertise-scott-coward-paul-kuznik BiopharmaWatch en 2026-09-28T12:00:00.000Z Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-expands-laboratory-capabilities BiopharmaWatch en 2026-09-28T12:00:00.000Z Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research https://www.biopharmawatch.com/news/ABBV/fda-approves-abbvie-juvmo-parkinsons-disease BiopharmaWatch en 2026-09-28T12:00:00.000Z U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease https://www.biopharmawatch.com/news/PVLA/fda-funding-qtorin-rapamycin-microcystic-lymphatic-malformations BiopharmaWatch en 2026-09-28T11:30:09.000Z U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations https://www.biopharmawatch.com/news/CGC/canopy-growth-appoints-sebastian-bloete-germany-manager BiopharmaWatch en 2026-09-28T11:30:00.000Z Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1530-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-09-28T11:30:00.000Z Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 https://www.biopharmawatch.com/news/IMRX/immuneering-2026-aacr-conference-atebimetinib-pancreatic-cancer BiopharmaWatch en 2026-09-28T11:30:00.000Z Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-yariv-houvras-cmo BiopharmaWatch en 2026-09-28T11:30:00.000Z Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer https://www.biopharmawatch.com/news/SCYX/scynexis-barda-contract-funding-scy-247 BiopharmaWatch en 2026-09-28T11:30:00.000Z SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-fda-removal-drug-limit BiopharmaWatch en 2026-09-28T11:30:00.000Z CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit https://www.biopharmawatch.com/news/MBRX/moleculin-announces-cardiac-safety-analysis-annamycin BiopharmaWatch en 2026-09-28T11:00:25.000Z Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine https://www.biopharmawatch.com/news/NAIA/naia-relief-alumni-perks-partnership-well-being-support BiopharmaWatch en 2026-09-28T11:00:00.000Z naia Relief Inc. Announces Strategic Partnership with Alumni-Perks to Expand Access to 24/7 Well-Being Support for Canadian University/College Alumni https://www.biopharmawatch.com/news/BRKR/bruker-advances-functional-proteomics-timsultra-timsomni BiopharmaWatch en 2026-09-28T11:00:00.000Z Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research https://www.biopharmawatch.com/news/ANTX/antx-funding-extension-tuberculosis-research-gsk BiopharmaWatch en 2026-09-28T11:00:00.000Z AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK https://www.biopharmawatch.com/news/CSTL/tissuecypher-study-management-non-dysplastic-barretts-esophagus BiopharmaWatch en 2026-09-28T11:00:00.000Z New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-banyan-trial-als-foralumab BiopharmaWatch en 2026-09-28T11:00:00.000Z Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-virtual-kol-event-denifanstat-update BiopharmaWatch en 2026-09-28T11:00:00.000Z Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-501284-aacr-conference BiopharmaWatch en 2026-09-28T11:00:00.000Z BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer https://www.biopharmawatch.com/news/ARVN/arvinas-phase-1-2-trial-arv-6723 BiopharmaWatch en 2026-09-28T11:00:00.000Z Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-launches-impavido-capsules BiopharmaWatch en 2026-09-28T10:50:00.000Z Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules https://www.biopharmawatch.com/news/PFE/pfizer-cancer-care-esmo-2026 BiopharmaWatch en 2026-09-28T10:45:00.000Z Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO https://www.biopharmawatch.com/news/PFE/pfizer-advances-cancer-care-esmo-2026 BiopharmaWatch en 2026-09-28T10:45:00.000Z Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO https://www.biopharmawatch.com/news/MRK/merck-exclusive-license-agreement-sci-brunch-spr2015 BiopharmaWatch en 2026-09-28T10:45:00.000Z Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor https://www.biopharmawatch.com/news/ACET/adicet-bio-prula-cel-safety-efficacy-data-sle BiopharmaWatch en 2026-09-28T10:45:00.000Z Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://www.biopharmawatch.com/news/KOD/zenkuda-tabirafusp-ted-daybreak-trial-wamd BiopharmaWatch en 2026-09-28T10:30:00.000Z Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria. https://www.biopharmawatch.com/news/WELL/well-health-wellstar-tsxv-listing-approval BiopharmaWatch en 2026-09-28T10:00:00.000Z WELL Health Subsidiary WELLSTAR Announces Conditional Approval for TSXV Listing and Files Filing Statement https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-dr-michael-white-promotion BiopharmaWatch en 2026-09-28T10:00:00.000Z IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development https://www.biopharmawatch.com/news/ZYME/zymeworks-theravance-biopharma-acquisition-financial-guidance BiopharmaWatch en 2026-09-28T10:00:00.000Z Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition https://www.biopharmawatch.com/news/MNOV/medicinova-topline-results-mn-001-natg-202-trial BiopharmaWatch en 2026-09-28T10:00:00.000Z MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) https://www.biopharmawatch.com/news/SNZZF/senzime-financing-oem-expansion-profitability BiopharmaWatch en 2026-09-28T09:20:00.000Z Senzime Strengthens Financing to Support Strategic OEM Expansion and Path to Profitability https://www.biopharmawatch.com/news/NNVC/clinical-trial-nv-387-ebola-enrollment-dosing BiopharmaWatch en 2026-09-28T08:45:00.000Z Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides https://www.biopharmawatch.com/news/YI/111-inc-establishes-special-committee BiopharmaWatch en 2026-09-28T08:30:00.000Z 111, Inc. Announces Establishment of the Special Committee https://www.biopharmawatch.com/news/COSM/cosmos-health-cmo-pipeline-revenue-growth BiopharmaWatch en 2026-09-28T08:00:00.000Z Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-28 BiopharmaWatch en 2026-09-28T07:15:32.098Z IGALMI PDUFA for Agitation in Bipolar Disorder: Biotech Catalysts Sep 28, 2026 https://www.biopharmawatch.com/news/STAA/staars-consumer-survey-vision-correction-germany BiopharmaWatch en 2026-09-28T07:00:00.000Z Verbraucherumfrage von STAAR Surgical: 71 Prozent der Deutschen möchten auf Sehhilfen verzichten, kennen aber ihre Alternativen nicht https://www.biopharmawatch.com/news/TMO/thermo-fisher-evosep-reseller-agreement BiopharmaWatch en 2026-09-28T07:00:00.000Z Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno https://www.biopharmawatch.com/news/MEDS/datameds-ai-tollo-health-launch-health-lives-here-app BiopharmaWatch en 2026-09-28T06:00:00.000Z DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application https://www.biopharmawatch.com/news/DXCM/dexcom-report-easd-2026-diabetes-care-opportunity BiopharmaWatch en 2026-09-28T06:00:00.000Z Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care https://www.biopharmawatch.com/news/IVA/inventiva-reports-2026-first-half-financial-results BiopharmaWatch en 2026-09-28T06:00:00.000Z Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-bacteria-panel BiopharmaWatch en 2026-09-28T05:30:00.000Z QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-2026-half-year-results-update BiopharmaWatch en 2026-09-28T05:00:00.000Z Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update https://www.biopharmawatch.com/news/PTN/palatin-fiscal-year-2026-results-business-update BiopharmaWatch en 2026-09-28T00:00:00.000Z Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity,... https://www.biopharmawatch.com/news/LLY/lilly-change-course-commitment-diabetes-obesity-lmics BiopharmaWatch en 2026-09-28T00:00:00.000Z Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, ... https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-call-azure-1-study BiopharmaWatch en 2026-09-27T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026